Skip to main content
Premium Trial:

Request an Annual Quote

Pfizer Inks Deal for Access to Centogene Rare Disease Data

NEW YORK — Centogene said on Wednesday that it has signed an agreement giving access to its rare disease data repository to Pfizer for use in the discovery of novel drug targets.

Centogene said the repository includes a range of rare disease patient data including clinical information, health records, and genetic, transcriptomic, proteomic, and metabolomic data. It also contains longitudinal data such as biomarkers or patient recorded outcomes, as well as diagnostic workflow data.

Under the terms of the deal, Centogene will help New York City-based Pfizer mine data from the repository, as well as substantiate the resulting data. In exchange, Centogene will receive an unspecified upfront payment and is eligible for future payments related to any additional collaborative research projects.

Additional terms were not disclosed. 

"With what we believe to be the world's largest data repository of epidemiologic, phenotypic and clinical data in orphan diseases, Centogene is fueling the global knowledge base of rare disease patient populations," Centogene CEO Arndt Rolfs said in a statement.

Earlier this month, Rostock, Germany-based Centogene went public on the Nasdaq at $14 per share. During early Wednesday morning trading, the company's stock was up 3.5 percent at $14.24.